Podcast Episodes
Back to SearchTreat to Target: What it Is and How to Implement
Episode 553
Drs. Chaichian and Dall’Era explore the “treat to target” approach in lupus, including key targets like DORIS remission and lupus low disease activit…
11 months ago
Earlier Use of Biologics for Treating Lupus
Episode 552
Drs. Dall’Era and Chaichian discuss earlier use of targeted biologics for treating lupus.
11 months, 1 week ago
Is FDA-backed elastography poised to replace biopsy as the driver of MASH drug development?
Episode 551
The FDA has endorsed vibration-controlled transient elastography as a surrogate endpoint for MASH trials, marking the first non-invasive alternative …
11 months, 1 week ago
2025 Guideline Summary for the Clinical Treatment and Management of Systemic Lupus Erythematosus
Episode 550
Drs. Chaichian and Dall’Era review the updated guidelines for the treatment and management of SLE in children and adults.
11 months, 1 week ago
Emerging Therapies in SLE: Recent Studies and Potential Game-Changing Treatments
Episode 549
Drs. Fava and Petri discuss emerging therapies in systemic lupus erythematosus, including treatments for lupus nephritis and cutaneous disease.
11 months, 2 weeks ago
Non-Invasive Biomarkers in SLE: A Promise of Better Diagnosis, Management, and Personalized Treatment?
Episode 548
Drs. Petri and Fava review non-invasive biomarkers in systemic lupus erythematosus, including urine proteomics.
11 months, 2 weeks ago
New Guidelines for the Screening, Treatment, and Management of Lupus Nephritis
Episode 547
Drs. Petri and Fava discuss updated guidelines for the screening, treatment, and management of lupus nephritis.
11 months, 2 weeks ago
What does FDA’s approval of generic liraglutide mean for obesity care?
Episode 546
The FDA has approved a generic version of liraglutide injection, expanding access to obesity treatment by lowering costs and broadening eligibility a…
11 months, 2 weeks ago
How will the first approval for MASH with fibrosis alter treatment pathways?
Episode 545
The FDA has granted accelerated approval to semaglutide (Wegovy) as the first drug for metabolic dysfunction–associated steatohepatitis (MASH), showi…
11 months, 3 weeks ago
How are telehealth abortion prescriptions reaching ban states?
Episode 544
A new JAMA study found that 84% of abortion prescriptions from Aid Access went to patients in states with bans, enabled by “shield laws” protecting t…
1 year ago